All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Antiretroviral therapy (ART) of HIV infection is effective at increasing quality of life and preventing HIV transmission, progression to AIDS, and death \[[@pone.0174613.ref001]\]. Suppression of HIV viral load to below detectable limits is the key predictor of efficacy \[[@pone.0174613.ref002], [@pone.0174613.ref003]\]. Once ART is initiated, it must be continued daily for life \[[@pone.0174613.ref004]\]. At least 95% adherence is recommended \[[@pone.0174613.ref005]\], including for contemporary, single-tablet, once-daily ART regimens \[[@pone.0174613.ref006]\]. One study comparing two single-tablet, initial ART regimens found that virological suppression at 48 weeks was 88--91% in those with ≥95% adherence, 75--79% with 90--95% adherence, but only 56--70% with \<90% adherence \[[@pone.0174613.ref007]\]. Others have found virological response falls from 89--99% at \>95% adherence to 62--75% with ≤95% adherence \[[@pone.0174613.ref006], [@pone.0174613.ref008]\].

Despite its benefits, not all patients fully adhere to ART. Non-adherence encompasses ART interruption as well as ongoing ART use with missed doses. A global meta-analysis estimated 90% ART adherence rates to be only 62% \[[@pone.0174613.ref009]\]. In Australia, which provides highly subsidised ART to all citizens and permanent residents, an estimated 92% of people on ART achieve viral suppression \[[@pone.0174613.ref010]\]. However, some patients who achieve virological suppression subsequently experience treatment failure (in Australia, about 3.5% per year \[[@pone.0174613.ref011]\]).

Australian permanent residents and citizens are able to access subsidised ART through the Pharmaceutical Benefits Scheme. Some patients contribute to the cost of their medicine (a co-payment), with a safety net in place to reduce these costs following meeting the annually-determined threshold. In some circumstances, patients can qualify for a concession card to further reduce their contribution (e.g. social welfare recipients, pensioners, department of veterans' affairs, etc.). Despite these subsidies, medicine costs in Australia have been noted to be moderate to high in comparison to other OECD countries \[[@pone.0174613.ref012]\], and even low co-payments have been identified as a potential barrier to accessing medications \[[@pone.0174613.ref013]\] \[[@pone.0174613.ref014]\]. Although narrowing, gaps remain in participation in paid employment and other social determinants of health (e.g. education) in HIV-positive adults in Australia \[[@pone.0174613.ref015]\].

Reasons for suboptimal ART adherence in resource-rich countries in a contemporary setting are not well understood \[[@pone.0174613.ref016]\]. Much of the literature on adherence pre-dates the era of single tablets regimens, or treatment as prevention \[[@pone.0174613.ref017], [@pone.0174613.ref018]\]. Factors individually associated with lower adherence include complex medication regimens (more than one tablet or dosing time per day) \[[@pone.0174613.ref019], [@pone.0174613.ref020]\], ART toxicity \[[@pone.0174613.ref021]\], ART costs and financial stress \[[@pone.0174613.ref022]\], attitudes and beliefs about ART necessity \[[@pone.0174613.ref023], [@pone.0174613.ref024]\], concerns about ART (e.g. side effects, reliance on ART) \[[@pone.0174613.ref024]\], poor relationships with healthcare providers, sociocultural relationship factors (e.g. unsupportive social networks), substance abuse \[[@pone.0174613.ref025]\], and HIV-associated neurocognitive disorders \[[@pone.0174613.ref026]\].

Prior studies of covariates of suboptimal ART adherence have several limitations. Many were not performed in the current era of simple, once-daily ART. Also, to the best of our knowledge, no study has comprehensively assessed the wide range of factors that may influence ART adherence, so it is unknown to what extent various factors are independently associated with adherence, nor which might be most associated. Furthermore, some potentially critical covariates have been studied infrequently. For example, an EMBASE / OVID search of the literature published between 2010 and 2016, with keywords (exploded) "HIV", "antiretroviral therapy", and "adherence" limited to adults and available in English language returned 291 results; adding "finance/finances/financial", returned two publications in the OECD context; including previous work completed by our group which did not evaluate an extensive range of variables \[[@pone.0174613.ref022]\]. We identified only one other study that reported the association between adherence and costs of ART to patients in a resource-rich setting \[[@pone.0174613.ref027]\]. Furthermore, most of the available literature in the OECD setting reports on findings from the United States, which may not be generalizable to the Australian demographic.

To increase our understanding of adherence behaviours, we conducted a cross-sectional analysis of the baseline sample, investigating a large number of patient, treatment, and socio-economic characteristics to determine the extent and predictors of suboptimal ART adherence in HIV-infected adults in Australia despite a suppressed viral load.

Methods {#sec006}
=======

Study design and setting {#sec007}
------------------------

We established a national, 2-year cohort study of HIV-infected adults on ART with an undetectable viral load. Participants were enrolled at 17 Australian general practice, sexual health, and hospital outpatient clinics between September 2013 and November 2015.

Ethical approval was obtained from the Human Research Ethics Committee at each study site. Written, informed consent was obtained from each participant prior to any study activity. Approving HREC names and approval reference numbers are: St Vincent's Hospital HREC (HREC/12/SVH/186), ACT Health Canberra HREC (ETH.7.13.178), Government of Western Australia South Metropolitan Health Service HREC (ref 13/70), The Alfred Hospital HREC (444/14) and Monash Health HREC (15O28X).

To avoid selection bias (e.g. selecting only those patients who were compliant and would complete the questionnaire), site co-ordinators (usually a research nurse) were instructed to invite all eligible patients during routine clinics, until each site reached its predetermined sample size (proportional to its estimated eligible patient population and capacity to recruit). The aim was to recruit a representative sample of patients at each site and, to not exclude patients deemed at risk of ART failure for any reason. This allowed all patients seen at the study sites over the recruitment period an equal opportunity of participation in the cohort.

Participants {#sec008}
------------

HIV-infected adults (≥18 years of age) were eligible if they were on ART, had an HIV viral load less than 50 copies/mL plasma (at enrolment or on most recent assessment), could complete the study questionnaire (with the assistance of an interpreter, if required), and had HIV viral load, CD4 T-lymphocyte count, full blood count and biochemistry results in the last 3 months.

Assessments {#sec009}
-----------

### Questionnaire {#sec010}

Using a study-provided laptop computer, participants complete a 204-question questionnaire (divided between 124 items and 13 themes) at baseline, Month 12, and Month 24 (this report focuses on the baseline data only). Questionnaire feasibility had been tested in a pilot study, which found a mean completion time of 40 minutes with 99% data completion \[[@pone.0174613.ref028]\].

The annual patient self-completed questionnaire incorporates a series of measures \[[@pone.0174613.ref022], [@pone.0174613.ref029]--[@pone.0174613.ref039]\], assessing the following categories (themes) of variables: socio-demographic characteristics (18 items), financial and employment status (8 items), income (2 items), healthcare and treatment access (19 items), physical health (5 items), mental health (2 items), quality of life (1 item), drug and alcohol use (19 items), life stressors and social supports (3 items), HIV disclosure and perceived or experienced stigma (5 items), ART regimen, side effects, consistent use, and dose adherence (24 items), ART-related necessity beliefs and concerns (10 items), non-ART medication (8 items). [Table 1](#pone.0174613.t001){ref-type="table"} includes the detailed measures, the majority either existing (e.g. SMAQ \[[@pone.0174613.ref038]\], PHQ-9 \[[@pone.0174613.ref035]\] \[[@pone.0174613.ref036]\], CAGE \[[@pone.0174613.ref039]\], see [Table 1](#pone.0174613.t001){ref-type="table"}) or pre-validated (e.g. the majority of those have been used among HIV-positive Australians, see [Table 1](#pone.0174613.t001){ref-type="table"}). From the 43-item PROQOL-HIV scale \[[@pone.0174613.ref037]\]), 41 items were maintained, and two original items (general health and the impact of ART-related side-effects on treatment adherence items) were replaced by separate questions on general health (without the limitation of the past two-week timeframe) and a more detailed set of questions on ART side effects in our study.

10.1371/journal.pone.0174613.t001

###### Questionnaire composition.

![](pone.0174613.t001){#pone.0174613.t001g}

  Heading                                                    Number of Items   Item clusters                                                                                                                                                                                                                                   Embedded items / literature source
  ---------------------------------------------------------- ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographics                                               18                age, sex, sexual orientation, country of birth, citizenship status, English fluency, Medicare status, partner, household, education                                                                                                             Positive Health (ph) Cohort \[[@pone.0174613.ref029]\]
  Physical health                                            5                 prior AIDS, hospitalizations, time in bed / off work due to illness                                                                                                                                                                             Positive Health (ph) Cohort \[[@pone.0174613.ref029]\]
  Mental health / emotional wellbeing                        22                mood, alcohol and illicit drug use                                                                                                                                                                                                              Patient Health Questionnaire (PHQ-9) \[[@pone.0174613.ref035], [@pone.0174613.ref036]\], Professional Quality of Life Scale (the PROQOL-HIV scale) \[[@pone.0174613.ref037]\], CAGE \[[@pone.0174613.ref039]\] questionnaire for alcohol dependence
  Life stressors, social support                             3                 Events, severity, social network                                                                                                                                                                                                                The Positive Health (ph) Cohort \[[@pone.0174613.ref029]\]
  HIV disclosure, stigma                                     5                 Disclosure, stigma, discrimination                                                                                                                                                                                                              National Association of People With HIV Australia (NAPWHA) HIV Stigma Audit's Community Survey \[[@pone.0174613.ref034]\], Professional Quality of Life Scale (the PROQOL-HIV scale)\[[@pone.0174613.ref037]\]
  Health and treatment perception                            10                Attitudes to ART and HIV, adverse events, mood                                                                                                                                                                                                  Chronic Illness Acceptance Questionnaire \[[@pone.0174613.ref033]\], Pleasure and Sexual Health (PASH) study \[[@pone.0174613.ref032]\]; Beliefs About Medications Scales (BMQ-HAART) \[[@pone.0174613.ref031]\]
  HIV healthcare access, treatment adherence, side effects   51                Current / prior ART and concomitant medications: doses and pills / day, dosing requirements, side effects, adherence to treatments doctors and allied health professional: frequency of attendance, changes to healthcare team, costs of care   Simplified Medication Adherence Questionnaire (SMAQ) \[[@pone.0174613.ref038]\],
  Financial and employment status                            10                Income, life costs, healthcare costs                                                                                                                                                                                                            St Vincent's Immunology B Ambulatory Care's finance and adherence survey \[[@pone.0174613.ref022]\]

Participants were asked if they had met the Medicare Safety Net threshold, this threshold provides financial relief for medical services covered under the Medicare benefits system (e.g. a discounted patient co-payment for prescribed pharmaceuticals). In 2015, the Medicare safety net threshold was A\$2,000 for a regular Medicare holder, and A\$638.40 for a concessional status cardholder \[[@pone.0174613.ref040]\].

### Neurocognitive assessment {#sec011}

For the present analysis, neurocognitive function was assessed at baseline using computerized screening (Cogstate brief battery \[[@pone.0174613.ref041]\]) (future analyses will include data from Months 12 and 24). The Cogstate brief battery includes four tasks (detection, identification, one back and the one-card learning tasks) examining: processing speed, sustained attention, divided attention, visual learning and working memory \[[@pone.0174613.ref041]\]; and has previously been validated as a reliable screening tool in HIV-positive adults similar to the currently enrolled cohort \[[@pone.0174613.ref042]\]. Z-scores for each of four domains were generated using Cogstate normative standards \[[@pone.0174613.ref042]\] and were used to calculate a global deficit score (GDS) \[[@pone.0174613.ref043], [@pone.0174613.ref044]\]. Adjustments were not made for depression or substance use because neither correlated with GDS in this sample (p = 0.122 and p = 0.63 respectively) \[[@pone.0174613.ref045]\]. The standard GDS of \>0.5 (averaged over four tasks \[[@pone.0174613.ref043]\]) was used as the cut-off point for cognitive impairment, and was analysed using the dichotomous classification of impaired or unimpaired.

### Antiretroviral dispensing records {#sec012}

ART dispensing data for the 12 months preceding the baseline assessment were collected from every ART-dispensing pharmacy serving each study participant. Data collected are: antiretroviral medications dispensed, months dispensed, total cost to patient (inclusive of any patient co-payment), and whether medication(s) were obtained via a clinical trial.

### Clinical and laboratory data {#sec013}

The study coordinator collects clinical and laboratory data semi-annually for the duration of follow-up including: medical history; HIV history (date and mode of transmission, past AIDS-defining illnesses, opportunistic infections, serious non-AIDS events \[[@pone.0174613.ref046]\]); ART history (date of commencement, components and duration of current regimen, pill burden, dosing frequency and requirements, duration of undetectable HIV viral load); concomitant medications; comorbidities; sexually transmitted infections; and patient retention in care (number of attendances, missed appointments, clinical trial enrolment, directly-observed therapy). Laboratory data collected are: HIV viral load, CD4+ T-lymphocyte counts (current and nadir), haemoglobin, estimated glomerular filtration rate (eGFR) and alanine aminotransaminase (ALT).

Outcome variable {#sec014}
----------------

The main outcome variable for the present analysis of the baseline data was ART adherence over the previous three months as reported by participants at study entry. Given the cohort design, all participants included at baseline had an undetectable viral load within three months prior to enrolment. As the main study objective is to identify risk for adherence over time, the cohort data will be analysed in future (when data become available), for participants who experience ART failure. For the present analysis, we were interested in ascertaining the actual adherence of this virologically controlled sample. Given the requirement of \>95% adherence to ART, even in contemporary regimens, missing greater than one dose per month places a patient at risk of virological failure. Therefore, suboptimal adherence was defined as an average of at least 1 missed ART dose per month over the previous three months \[[@pone.0174613.ref006], [@pone.0174613.ref007]\], based on participant self-report. This was ascertained by asking participants how many ART doses were missed/skipped in the previous 3-months.

Participants taking once-daily ART (by single tablet regimen or otherwise) who missed one ART dose per month or more were considered to have had suboptimal adherence. Those participants who took twice-daily ART and missed doses at a threshold of \>2 doses per month for three months were considered sub-optimally adherent. For the 23 participants taking twice-daily ART who missed less than two doses per month for three months (but missed more than one dose per month; e.g. missing 5 doses over the 3-month period), additional sensitivity analysis was conducted.

Sample size {#sec015}
-----------

The main study was powered based on a previous study conducted by our group that showed 9% of patients had ceased or interrupted medication, and 29% of those who had difficulty meeting pharmacy costs had ceased medication \[[@pone.0174613.ref022]\]. Assuming characteristics associated with non-adherence would be more prevalent in the non-adherent group, a sample size of 500 was sufficient to give 85% power to detect an odds ratio ≥3 for associations with a covariate, with a prevalence of 29% in the sub-optimally adherent versus adherent participants, at a 2-sided significance level of 5%.

Statistical methods {#sec016}
-------------------

For items that were part of a validated scale, results were used to generate a summary score as intended (e.g. PHQ9 for depression \[[@pone.0174613.ref035]\], PROQOL-HIV \[[@pone.0174613.ref037]\] and CAGE for alcohol abuse \[[@pone.0174613.ref039]\]). Categorical data were re-coded into binary responses (e.g. housing: subsidized or not). Continuous data were dichotomized based on clinical significance where supported (e.g. ALT, eGFR) or on sample median or mean values, depending on distribution (e.g., median/mean split). Those continuous data dichotomised by sample median / mean included: age, income, duration of care from primary HIV physician, cost of healthcare / alternative healthcare services over previous 12-months, money spent last time HIV medication was obtained, money spent in previous 3-months on non-HIV medications, cost of all healthcare needs, CD4 T-lymphocyte cell count, missed clinical appointments, number of life stressors, and concomitant medication pill burden. Data dichotomised by a reference point included: year HIV diagnosed (prior to 1996), nadir CD4 (\<200), length of undetectable HIV viral load (\>12 months), ART year commenced (prior to 2004), haemoglobin (\<130g/L males, \<120 g/L females), ALT (\>40 U/L males, \>35 U/L females), eGFR (\<90), hospitalisations / inpatient days (\>1), bed days due to illness (\>1), doctors' visits due to illness (\>1).

Bivariate associations between adherence and all covariates were assessed. Where individual items were correlated, we selected the one showing the most significant relationship with the outcome variable to avoid multi-collinearity. After assessing all covariates for significance, all of those variables significantly (p\<0.05) associated with suboptimal adherence in bivariate analysis were included in a multivariable logistic regression analysis using the Enter method, whereby all variables are entered (forced) into the equation simultaneously.

The multivariable logistic regression methodology was chosen to help explore specific covariates that were associated with suboptimal adherence, rather than using data reduction to identify thematic associations, as a goal of the present analysis was to provide clinicians with specific variables to help identify less adherent patients.

Sensitivity analyses were performed using backward-stepwise and forward-stepwise approaches. Additional sensitivity analysis was conducted after reclassifying those on twice-daily ART dosing who potentially missed less than 2 doses of ART per month in the previous 3 months (e.g. missing 5 doses over the previous three months) from the non-adherent to the adherent group.

All statistical analyses were conducted in IBM SPSS Statistics for Windows, Version 22.0.

Results {#sec017}
=======

Main demographic and clinical characteristics {#sec018}
---------------------------------------------

Of the 523 participants enrolled, one (0.2%) did not respond to the primary outcome measure and was excluded from this analysis. Of the 522 participants analysed, 203 (38.9%) were enrolled at sexual health clinics, 174 (33.3%) at hospital clinics, and 145 (27.8%) at HIV high-caseload general practices (sample characteristics are outlined in [Table 2](#pone.0174613.t002){ref-type="table"}). Four-hundred-ninety-four (94.6%) participants were male, and participants had a mean age of 50.8 (SD 12.3) years. Three-hundred twenty-two participants (61.6%) were Australian-born. Two-hundred twenty-six (43.3%) participants were in a relationship, of which 136 (26.1%) were with HIV serodiscordant partners.

10.1371/journal.pone.0174613.t002

###### Sample characteristics.

![](pone.0174613.t002){#pone.0174613.t002g}

  Variables                                                                                                                               n (%) or mean (SD)
  --------------------------------------------------------------------------------------------------------------------------------------- --------------------
  **Demographic characteristics**                                                                                                         
   Age (years; mean, SD)                                                                                                                  50.8 (12.3)
   Gender (Male)                                                                                                                          494 (94.6)
   Men who have sex with men                                                                                                              410 (78.5)
   Australian born                                                                                                                        322 (61.6)
   Living alone                                                                                                                           212 (40.5)
   Speaks English at home                                                                                                                 493 (94.3)
   Ability to read, speak and understand English rated as 'excellent'                                                                     427 (81.6)
   Australian citizen                                                                                                                     461 (88.1)
   Has Medicare access                                                                                                                    508 (97.1)
   Met the Medicare safety net[^a^](#t002fn001){ref-type="table-fn"} in previous 12-months                                                94 (18.0)
   Has private health insurance                                                                                                           221 (42.3)
   Lives in a major city                                                                                                                  452 (86.4)
   University educated                                                                                                                    197 (38.0)
  **Financial / employment status**                                                                                                       
   On social welfare                                                                                                                      212 (40.6)
   Required financial assistance in previous 12 months                                                                                    138 (26.4)
   No employment                                                                                                                          226 (43.2)
   Underemployment (would increase hours if available)                                                                                    220 (42.1)
   Current weekly income after tax (median, IQR)                                                                                          645 (580)
   Lives in public-subsidized accommodation                                                                                               105 (20.1)
   Lives with someone who is financially dependent on them                                                                                48 (9.2)
   Received financial assistance in previous 12 months                                                                                    
    from family                                                                                                                           42 (21.8)
    from Centrelink[^b^](#t002fn002){ref-type="table-fn"}                                                                                 97 (50.3)
    from partner                                                                                                                          18 (9.3)
    from non-governmental organization                                                                                                    80 (41.4)
   In previous 12 months, for financial reasons, had to forego food, groceries, rent, household bills, furniture, clothing, white goods   114 (21.8)
  **HIV healthcare and treatment access**                                                                                                 
  Uses the following for HIV management:                                                                                                  
    hospital based HIV clinic                                                                                                             254 (48.7)
    health center specialized in HIV treatment                                                                                            135 (25.9)
    community based general practice                                                                                                      174 (33.3)
    sexual health clinic / center                                                                                                         168 (32.2)
    naturopath                                                                                                                            26 (5.0)
    hospital pharmacy                                                                                                                     259 (49.6)
    home or community care                                                                                                                14 (2.3)
    drug or alcohol services                                                                                                              9 (1.7)
    HIV-related community organizations or support groups                                                                                 77 (14.8)
  Primary HIV physician                                                                                                                   
    general practitioner                                                                                                                  181 (34.7)
    hospital physician                                                                                                                    223 (42.7)
    sexual health physician                                                                                                               114 (21.8)
  Study enrolment site                                                                                                                    
    high-caseload general practice                                                                                                        145 (27.8)
    hospital located clinic                                                                                                               174 (33.3)
    sexual health clinic / center                                                                                                         203 (38.9)
  Feels actively involved in the management / treatment of HIV                                                                            506 (96.9)
   Consults with primary HIV physician at least every six months                                                                          512 (98.1)
   Duration of care from primary HIV physician (years: mean, SD)                                                                          11.3 (8.0)
   Changed primary HIV physician in previous 12 months                                                                                    80 (15.3)
   No payment required from patient for HIV consultations                                                                                 288 (82.8)
   Has seen other medical specialists in the previous 12 months                                                                           321 (61.5)
   Has other healthcare providers involved in HIV care                                                                                    324 (62.1)
   Cost of healthcare services over previous 12 months (dollars: mean, SD)                                                                281 (616)
   Cost of alternative healthcare services over previous 12 months (dollars: mean, SD)                                                    675 (1161)
   Cost a barrier to accessing medical services in the previous 12 months                                                                 71 (13.6)
   ART pharmacy charges a patient co-payment                                                                                              292 (55.8)
   Money spent last time HIV medication obtained (dollars: mean, SD)                                                                      106 (410)
   Money spent in previous three months on non-HIV medication (dollars: mean, SD)                                                         145 (434)
   Cost of all health needs (except medications) in previous 3 months (dollars: mean, SD)                                                 303 (1135)
  **HIV history**                                                                                                                         
   HIV diagnosed prior to 1996                                                                                                            213 (40.8)
   Male-to-male sexual transmission of HIV                                                                                                406 (77.6)
   Nadir CD4 T-lymphocyte count \<200 cells                                                                                               202 (38.7)
   Previous AIDS                                                                                                                          120 (22.9)
  **Comorbidities**                                                                                                                       
   Heart disease                                                                                                                          57 (10.9)
   Hypertension                                                                                                                           94 (18.0)
   Stroke                                                                                                                                 9 (1.7)
   Peripheral vascular disease                                                                                                            8 (1.50)
   Diabetes                                                                                                                               31 (5.9)
   Chronic liver failure                                                                                                                  2 (0.4)
   Chronic kidney disease                                                                                                                 14 (2.7)
   Other diagnosed comorbidity                                                                                                            102 (19.5)
  **Current health**                                                                                                                      
   CD4 T-lymphocyte count (mean, SD)                                                                                                      659 (273)
   Length of undetectable HIV viral load \>1 year                                                                                         399 (76.4)
   Currently enrolled on a clinical trial                                                                                                 45 (8.6)
   Anaemia[^c^](#t002fn003){ref-type="table-fn"}                                                                                          33 (6.3)
   Elevated ALT[^d^](#t002fn004){ref-type="table-fn"} (\>40 U/L males, \>35 U/L females)                                                  130 (24.9)
   eGFR[^e^](#t002fn004){ref-type="table-fn"} \<90 mls/min/1.73m2                                                                         290 (55.6)
   Hepatitis co-infection                                                                                                                 70 (13.4)
   Sexually transmitted infection in previous 12-months                                                                                   71 (13.6)
   Hospitalized for ≥1 night in previous 12 months                                                                                        108 (20.7)
   Missed ≥1 clinic appointment in previous 12 months                                                                                     71 (13.6)
  **Physical health**                                                                                                                     
   Self-reported good / very good overall health                                                                                          435 (83.3)
   One or more bed days due to illness in previous 12 months                                                                              284 (54.4)
   One or more doctor visits due to illness in previous 12 months                                                                         358 (68.6)
   Greater than one hospital inpatient day in previous 12 months                                                                          100 (19.2)
  **Mental health**                                                                                                                       
   Major depressive disorder on PHQ-9\[[@pone.0174613.ref035], [@pone.0174613.ref036]\]                                                   87 (16.7)
   Psychiatric illness---currently clinically active                                                                                      112 (24.3)
  **Cognitive function**                                                                                                                  
   Neurocognitive impairment                                                                                                              148 (28.3)
  **Alcohol and drug use**                                                                                                                
   Alcohol dependent (CAGE\[[@pone.0174613.ref039]\])                                                                                     106 (20.3)
   Use of following drugs monthly or more in previous 12 months:                                                                          
    cigarettes                                                                                                                            143 (27.4)
    marijuana / hash                                                                                                                      94 (18.0)
    amyl / poppers                                                                                                                        67 (12.8)
    benzodiazepines                                                                                                                       39 (7.5)
    ecstasy                                                                                                                               1 (0.2)
    injected speed / amphetamines                                                                                                         20 (3.8)
    snorted or smoked speed / amphetamines                                                                                                17 (3.3)
    injected cocaine                                                                                                                      2 (0.4)
    snorted cocaine                                                                                                                       3 (0.6)
    crystal methamphetamine                                                                                                               23 (4.4)
    GHB / GBH / liquid E / fantasy                                                                                                        6 (1.1)
    LSD                                                                                                                                   2 (0.4)
    PDE5 inhibitor ("viagra" or 'similar')                                                                                                67 (12.8)
    heroin                                                                                                                                3 (0.6)
    methadone                                                                                                                             9 (1.7)
    opiates                                                                                                                               11 (2.1)
  **Life stressors**                                                                                                                      
   More than 2 major stress events in previous 12 months                                                                                  133 (25.5)
  **Social support**                                                                                                                      
   Married / de facto / in regular relationship                                                                                           226 (43.2)
   In a serodiscordant sexual relationship                                                                                                136 (26.0)
   Received less social support than wanted / needed                                                                                      302 (57.9)
   Not linked to an HIV support organization                                                                                              388 (74.3)
  **HIV disclosure, stigma and discrimination**                                                                                           
   Did not disclose HIV status                                                                                                            25 (4.8)
   Has been made to feel ashamed of HIV diagnosis                                                                                         224 (43.0)
   Has felt blamed for having HIV                                                                                                         173 (33.1)
   Has felt avoided, excluded or rejected for having HIV                                                                                  214 (41.0)
   Has had awkward interactions for having HIV                                                                                            248 (47.5)
  **Antiretroviral therapy**                                                                                                              
   ART as a single tablet regimen                                                                                                         158 (30.3)
   Once-daily ART dosing                                                                                                                  333 (63.7)
   Twice-daily ART dosing                                                                                                                 186 (35.6)
   ART requires fasting / food conditions                                                                                                 351 (67.2)
   Commenced ART within one year of diagnosis                                                                                             245 (46.8)
   Commenced ART prior to 2004                                                                                                            247 (47.3)
   Receiving ART through a clinical trial                                                                                                 28 (5.4)
   Receiving ART through directly observed therapy (DOT)                                                                                  8 (1.5)
   When started ART felt 'not at all' / 'only somewhat' informed about ART                                                                
    side effects                                                                                                                          178 (34.1)
    benefits                                                                                                                              115 (22.0)
    dosing requirements                                                                                                                   44 (8.4)
    lifestyle impacts                                                                                                                     151 (28.9)
    own ART regimen                                                                                                                       106 (20.3)
   Reason for starting ART:                                                                                                               
    to prevent HIV disease progression to AIDS                                                                                            325 (62.6)
    to reduce HIV symptoms                                                                                                                167 (32.2)
    to prevent transmission to HIV-negative partners                                                                                      101 (19.5)
    to prevent transmission to the community                                                                                              94 (18.1)
    due to high viral load                                                                                                                233 (44.9)
    due to low CD4 t-lymphocyte cell count                                                                                                263 (50.7)
    following doctor's advice                                                                                                             328 (63.2)
    following their own request                                                                                                           64 (12.3)
   Never speaks with HIV doctors or nurses about                                                                                          
    balancing ART regimen with overall health and lifestyle                                                                               174 (33.5)
    side effects associated with ART                                                                                                      101 (19.5)
    delaying, interrupting or changing ART                                                                                                250 (48.3)
    cost burden of ART                                                                                                                    425 (82.1)
   I forget to take ART medications                                                                                                       242 (46.4)
   I am careless at times about taking ART medications                                                                                    86 (16.5)
   Sometimes if I feel worse I stop taking ART medications                                                                                48 (9.2)
   Skipped ART once or more in the previous weekend                                                                                       35 (6.7)
   Experienced ART side effects in the previous 12 months                                                                                 297 (56.9)
   Experienced difficulties accessing pharmacy for ART                                                                                    32 (6.1)
   Missed ART once or more in the previous week                                                                                           83 (15.9)
   Delayed / interrupted ART in the previous 12 months                                                                                    34 (6.5)
   Delayed / interrupted ART in the previous 12 months for ≥1 week                                                                        20 (4.0)
   Doctor unaware of ART interruption / delay in previous 12 months                                                                       7 (1.3)
   Delayed / interrupted ART prior to 12 months ago                                                                                       85 (17.5)
   Delayed / interrupted ART prior to 12 months ago for ≥1 week                                                                           66 (12.6)
   Doctor unaware of prior ART interruption / delay                                                                                       14 (2.7)
  **ART necessity concerns**                                                                                                              
   Necessity concerns summary score[^f^](#t002fn006){ref-type="table-fn"} (mean, SD)                                                      62.0 (7.0)
  **Concomitant medications**                                                                                                             
   Daily concomitant medication pill burden (mean, SD)                                                                                    3.6 (4.3)
   Delayed / interrupted in previous 12 months                                                                                            60 (14.0)
   Delayed / interrupted in previous 12 months for ≥1 week                                                                                37 (7.1)
   Doctor unaware of interruption / delay in previous 12 months                                                                           27 (5.2)
   Delayed / interrupted prior to 12 months ago                                                                                           49 (12.3)
   Delayed / interrupted prior to 12 months ago for ≥1 week                                                                               32 (6.1)
   Doctor unaware of prior ART interruption / delay                                                                                       19 (3.6)
  **PRO-QOL HIV**                                                                                                                         
   PRO-QOL HIV summary score[^g^](#t002fn007){ref-type="table-fn"} (mean, SD)                                                             40.1 (23.4)

^a^ whereby medical costs---including pharmaceutical co-payments, are capped after reaching an annual threshold

^b^ social services

^c^ Anaemia defined by haemoglobin \<130g/L in men and \<120g/L in women\[[@pone.0174613.ref047]\]

^d^ ALT = alanine aminotransaminase

^e^ eGFR = estimated glomerular filtration rate

^f^ sample summary score (mean) (higher scores indicative of less belief in necessity or acceptability of ART)

^g^ sample summary score (mean) (higher score indicative of lower quality of life)

Mean CD4+ T-lymphocyte count was 659 cells/mm^3^ (SD 273), 122 (22.9%) had a prior AIDS-defining illness, and 70 (13.4%) had hepatitis B and/or C co-infection. Eighty-seven (16.7%) participants had symptoms consistent with a major depressive disorder and 148 (28.3%) were classified as neurocognitively impaired.

The median weekly after-tax income (including social welfare payments) was \$580 Australian dollars (about US\$422; €377), and median annualized healthcare expenditure was A\$598. Nearly all participants (507 \[97.1%\]) had Medicare coverage (publically-funded hospital and medical services), and 94 (18.0%) had reached the "Medicare safety net" in the previous 12 months. One-hundred thirty-eight (26.4%) participants had relied upon financial assistance to obtain basic necessities (e.g. rent, groceries, utilities) over the previous 12 months, and 114 (21.8%) participants had insufficient financial means to meet basic necessities over the previous 12 months. One-hundred-four (19.9%) participants lived in subsidized housing and 212 (40.6%) were on social welfare.

Seventy-seven (14.8%) participants were linked with one or more HIV community organizations / peer support groups as part of their HIV care, and 14 (2.3%) were receiving home-care services.

ART regimen and adherence {#sec019}
-------------------------

The median duration of undetectable HIV viral load was 3.3 years (IQR 1.2--6.8 years), and the median ART duration was 11.0 years (IQR 5--19 years), with 137 (26.3%) participants on their current ART regimen for no more than 12 months. Three-hundred thirty-three participants (63.8%) were taking once-daily ART and 158 (30.3%) were taking a single-tablet ART regimen; 352 participants (67.4%) were on regimens with specific food / fasting requirements. Two-hundred eleven (40.4%) participants were on a non-nucleoside reverse-transcriptase inhibitor (NNRTI) and nucleoside / nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) regimen, 99 (19.0%) were on an NRTI plus integrase strand transfer inhibitor (INSTI) regimen, 79 (15.1%) were on an NRTI plus protease inhibitor (PI) regimen, and 133 (25.5%) were on an alternative regimen (predominantly 3-class or NRTI-sparing). Three-hundred twenty-eight participants (62.8%) had started ART following advice from their treating doctor, while 64 participants (12.3%) had started ART following their own request; 195 participants (37.4%) had started treatment to prevent transmission to partners or their community.

Seventy-eight participants (14.9%) reported missing an average of at least one ART dose per month over the previous 3 months ([Table 3](#pone.0174613.t003){ref-type="table"}). Associations with covariates in bivariate analyses are shown in [Table 4](#pone.0174613.t004){ref-type="table"}. The multivariable logistic regression model was statistically significant (x^2^ = 123(45), p\<0.001) and correctly classified 86.6% of cases. The final model contained 501 participants with 100% data collected on all included variables. Suboptimal ART adherence was independently associated with the following variables ([Table 5](#pone.0174613.t005){ref-type="table"}): being born in Australia; not being in a relationship; having reached the Medicare safety net threshold; living in subsidized housing; receiving home-care services; linkage to HIV community organizations; and having started ART at the patient's request. Those with more than three of these variables present had a particularly elevated rate of suboptimal ART adherence ([Table 6](#pone.0174613.t006){ref-type="table"}).

10.1371/journal.pone.0174613.t003

###### Self-reported ART adherence.

![](pone.0174613.t003){#pone.0174613.t003g}

                                                                                                  Yes         No
  ----------------------------------------------------------------------------------------------- ----------- ------------
  Missed ≥3 doses in previous 3 months                                                            78 (14.9)   444 (85.1)
  Delayed / interrupted ART for ≥1 week in the previous 12 months                                 20 (3.8)    502 (96.2)
  Ever delayed / interrupted ART (more than 12-months ago)[\*](#t003fn001){ref-type="table-fn"}   85 (16.3)   401 (76.8)

\*36 (6.9%) participant data missing / not applicable (e.g. not on ART prior to 12-months ago)

10.1371/journal.pone.0174613.t004

###### Variables associated with suboptimal ART adherence.

![](pone.0174613.t004){#pone.0174613.t004g}

  Variables                                                                                     Missed ART in last 3 months   OR[^1^](#t004fn001){ref-type="table-fn"}   95% CI[^2^](#t004fn002){ref-type="table-fn"}   P-value   
  ---------------------------------------------------------------------------------------- ---- ----------------------------- ------------------------------------------ ---------------------------------------------- --------- --
  **Socio-demographic**                                                                                                                                                                                                           
  Not currently in a relationship                                                          No   17                            207                                                                                                 
  Yes                                                                                      61   237                           3.1                                        1.8--5.5                                       \<0.001   
  Born in Australia                                                                        No   15                            186                                                                                                 
  Yes                                                                                      63   258                           3.0                                        1.7--5.5                                       \<0.001   
  Living alone                                                                             No   35                            276                                                                                                 
  Yes                                                                                      43   168                           2.0                                        1.2--3.3                                       0.004     
  Living in subsidized housing                                                             No   56                            362                                                                                                 
  Yes                                                                                      22   82                            1.7                                        1.0--3.0                                       0.047     
  Living outside of an urban area                                                          No   62                            391                                                                                                 
  Yes                                                                                      16   53                            1.9                                        1.0--3.5                                       0.039     
  HIV transmission route other than male-to-male sexual intercourse                        No   57                            370                                                                                                 
  Yes                                                                                      21   74                            1.9                                        1.1--3.2                                       0.030     
  **Finances and employment**                                                                                                                                                                                                     
  Medicare safety net[\*](#t004fn003){ref-type="table-fn"} reached in previous 12 months   No   49                            343                                                                                                 
  Yes                                                                                      29   101                           2.1                                        1.2--3.7                                       0.009     
  Having no private health insurance                                                       No   22                            199                                                                                                 
  Yes                                                                                      56   245                           2.1                                        1.2--3.5                                       0.006     
  Income ≤\$580 per week                                                                   No   28                            233                                                                                                 
  Yes                                                                                      50   211                           2.0                                        1.2--3.2                                       0.007     
  Unemployed                                                                               No   36                            260                                                                                                 
  Yes                                                                                      42   184                           1.8                                        1.1--2.9                                       0.019     
  Required financial assistance in the previous 12 months                                  No   39                            346                                                                                                 
  Yes                                                                                      39   98                            3.5                                        2.1--5.8                                       \<0.001   
  Going without for financial reasons (food, rent, etc.)                                   No   43                            365                                                                                                 
  Yes                                                                                      35   79                            3.8                                        2.3--6.3                                       \<0.001   
  Cost was a barrier to accessing HIV healthcare                                           No   61                            390                                                                                                 
  Yes                                                                                      17   54                            2                                          1.1--3.7                                       0.022     
  ART pharmacy expenditure \</ = sample mean monthly ART expenditure                       No   22                            187                                                                                                 
  Yes                                                                                      56   257                           1.9                                        1.1--3.1                                       0.021     
  **HIV healthcare and treatment access**                                                                                                                                                                                         
  Primary HIV care provided by a general practitioner                                      No   44                            304                                                                                                 
  Yes                                                                                      34   140                           1.7                                        1.0--2.7                                       0.037     
  Receives home care services                                                              No   70                            438                                                                                                 
  Yes                                                                                      8    6                             8.3                                        2.8--24.8                                      \<0.001   
  Receives drug and alcohol services                                                       No   74                            439                                                                                                 
  Yes                                                                                      4    5                             4.7                                        1.2--18.1                                      0.012     
  Linked to HIV community organisation(s)                                                  No   56                            389                                                                                                 
  Yes                                                                                      22   55                            2.8                                        1.6--4.9                                       \<0.001   
  Required other healthcare specialists in previous 12 months                              No   21                            180                                                                                                 
  Yes                                                                                      57   264                           1.9                                        1.1--3.2                                       0.023     
  Other healthcare providers were involved in HIV management                               No   16                            182                                                                                                 
  Yes                                                                                      62   262                           2.7                                        1.5--4.8                                       0.001     
  Having difficulty with ART pharmacy access                                               No   67                            423                                                                                                 
  Yes                                                                                      11   21                            3.3                                        1.5--7.2                                       0.001     
  **Physical health**                                                                                                                                                                                                             
  Self-rated health status as poor/very poor                                               No   56                            378                                                                                                 
  Yes                                                                                      22   66                            2.3                                        1.3--3.9                                       0.004     
  \>1 bed days for illness in previous 12 months                                           No   23                            215                                                                                                 
  Yes                                                                                      55   229                           2.5                                        1.5--4.4                                       0.001     
  ≥1 unscheduled doctor visits                                                             No   17                            147                                                                                                 
  Yes                                                                                      61   297                           1.8                                        1.0--3.3                                       0.045     
  ≥1 overnight hospitalization in previous 12 months                                       No   54                            360                                                                                                 
  Yes                                                                                      24   84                            1.9                                        1.1--3.3                                       0.017     
  Hepatitis co-infection                                                                   No   61                            393                                                                                                 
  Yes                                                                                      17   51                            2.1                                        1.2--4.0                                       0.013     
  HIV diagnosis prior to 1996                                                              No   38                            271                                                                                                 
  Yes                                                                                      40   173                           1.7                                        1.0--2.7                                       0.034     
  **Mental Health**                                                                                                                                                                                                               
  Major depressive disorder                                                                No   49                            386                                                                                                 
  Yes                                                                                      29   58                            3.9                                        2.3--6.7                                       \<0.001   
  **Alcohol and drug use (at least monthly)**                                                                                                                                                                                     
  Cigarette smoking                                                                        No   42                            337                                                                                                 
  Yes                                                                                      36   107                           2.7                                        1.6--4.4                                       \<0.001   
  Marijuana                                                                                No   52                            376                                                                                                 
  Yes                                                                                      26   68                            2.8                                        1.6--4.7                                       \<0.001   
  Benzodiazepine                                                                           No   63                            420                                                                                                 
  Yes                                                                                      15   24                            4.2                                        2.1--8.4                                       \<0.001   
  Injected speed                                                                           No   70                            432                                                                                                 
  Yes                                                                                      8    12                            4.1                                        1.6--10.4                                      0.001     
  Injected methamphetamines                                                                No   71                            428                                                                                                 
  Yes                                                                                      7    16                            2.6                                        1.0--6.6                                       0.033     
  Opiate use                                                                               No   74                            437                                                                                                 
  Yes                                                                                      4    7                             3.4                                        1.0--11.8                                      0.044     
  **Life stressors**                                                                                                                                                                                                              
  Major stressful event in the previous 12 months                                          No   20                            211                                                                                                 
  Yes                                                                                      58   233                           2.6                                        1.5--4.5                                       \<0.001   
  **HIV disclosure and stigma**                                                                                                                                                                                                   
  Have felt shamed/excluded /having awkward interactions since HIV diagnosis               No   21                            197                                                                                                 
  Yes                                                                                      57   247                           2.2                                        1.3--3.7                                       0.004     
  **ART regimen, side effects, consistent use and dose adherence**                                                                                                                                                                
  ART initiation prior to 2004                                                             No   30                            245                                                                                                 
  Yes                                                                                      48   199                           2.1                                        1.3--3.4                                       0.004     
  ART side effects                                                                         No   25                            200                                                                                                 
  Yes                                                                                      53   244                           1.7                                        1.0--2.9                                       0.033     
  On a multiple-tablet ART regimen                                                         No   15                            143                                                                                                 
  Yes                                                                                      63   301                           2.0                                        1.1--3.6                                       0.021     
  Greater than once-daily ART dosing                                                       No   40                            295                                                                                                 
  Yes                                                                                      38   149                           1.8                                        1.2--3.1                                       0.010     
  Feeling uninformed about ART when starting                                               No   65                            414                                                                                                 
  Yes                                                                                      13   30                            2.7                                        1.4--5.5                                       0.004     
  Starting ART following patient request                                                   No   61                            397                                                                                                 
  Yes                                                                                      17   47                            2.3                                        1.3--4.3                                       0.006     
  **ART-related necessity concerns**                                                                                                                                                                                              
  Necessity concerns score \> sample mean                                                  No   30                            247                                                                                                 
  Yes                                                                                      48   197                           2                                          1.2--3.3                                       0.005     
  **Non-ART medication consistent use and adherence**                                                                                                                                                                             
  Concomitant medication pill burden \>2 pills per day                                     No   31                            249                                                                                                 
  Yes                                                                                      47   195                           1.9                                        1.2--3.2                                       0.008     
  **Quality of Life**                                                                                                                                                                                                             
  PRO-QOL HIV score \> sample mean                                                         No   27                            271                                                                                                 
  Yes                                                                                      51   173                           3                                          1.8--4.9                                       \<0.001   

^1^Odds Ratio

^2^95% Confidence Interval

\*whereby medical costs---including pharmaceutical co-payments, are capped after reaching an annual threshold

10.1371/journal.pone.0174613.t005

###### Variables independently associated with suboptimal adherence.

![](pone.0174613.t005){#pone.0174613.t005g}

  Covariate                                                                                      Adjusted odds ratio   95% CI   P-value
  ---------------------------------------------------------------------------------------- ----- --------------------- -------- ---------
  Born in Australia                                                                        No                                   
  Yes                                                                                      2.4   1.2--4.9              0.014    
  Not in a relationship                                                                    No                                   
  Yes                                                                                      3.3   1.5--7.3              0.004    
  Medicare Safety Net[\*](#t005fn001){ref-type="table-fn"} reached in previous 12 months   No                                   
  Yes                                                                                      2.2   1.1--4.5              0.024    
  Living in subsidized housing                                                             No                                   
  Yes                                                                                      2.5   1.0--6.2              0.045    
  Receiving home care services                                                             No                                   
  Yes                                                                                      4.4   1.0--18.8             0.046    
  Linked to HIV community organisation(s)                                                  No                                   
  Yes                                                                                      2.4   1.1--5.4              0.033    
  Starting ART following patient request                                                   No                                   
  Yes                                                                                      3.0   1.3--7.0              0.012    

\*whereby medical costs---including pharmaceutical co-payments, are capped after reaching an annual threshold

10.1371/journal.pone.0174613.t006

###### Adherence according to number of independent variables present.

![](pone.0174613.t006){#pone.0174613.t006g}

  Number of independent variables[\*](#t006fn001){ref-type="table-fn"} present   n (%)        ART non-adherent   ART adherent   Odds Ratio (95%CI)   P-value[\*\*](#t006fn002){ref-type="table-fn"}
  ------------------------------------------------------------------------------ ------------ ------------------ -------------- -------------------- ------------------------------------------------
  0                                                                              47 (9.0)     4 (8.5)            43 (91.5)      1.0                  \-
  1                                                                              163 (31.2)   14 (8.6)           149 (91.4)     1.0 (0.3--3.2)       0.987
  2                                                                              194 (37.2)   25 (12.9)          169 (87.1)     1.6 (0.5--4.8)       0.408
  3                                                                              91 (17.4)    26 (28.6)          65 (71.4)      4.3 (1.4--13.2)      0.007
  4--7                                                                           27 (5.2)     9 (33.3)           18 (66.7)      5.4 (1.5--19.7)      0.007

\*As listed in [Table 5](#pone.0174613.t005){ref-type="table"}

\*\* P-trend \<0.0001

Sensitivity analyses {#sec020}
--------------------

Sensitivity analysis using backward-step and forward-step approaches yielded similar results ([Table 7](#pone.0174613.t007){ref-type="table"}). In sensitivity analysis, we examined the 38 participants on twice-daily ART, and following removal of 23 participants receiving twice-daily ART who missed less than 2 doses per month within the previous three months from the suboptimal group (thereby reclassifying them to the adherent group, but maintaining the 15 participants on twice-daily ART with more than two-missed doses per month within the previous three months as non-adherent), three predictor variables remained statistically significant (reaching the Medicare safety net, receiving home care services, and self-requesting ART); the other four predictors in the primary model were no longer statistically significant (relationship status, country of birth, subsidised housing, and accessing HIV community organisations). One variable became of borderline significance: injecting crystal methamphetamines (AOR 23.8; 95%CI 1.1--524.4; p = 0.045). Of these 23 participants, 11 were prescribed a once-daily ART co-formulated nucleoside backbone (either tenofovir with emtricitabine or abacavir with lamivudine).

10.1371/journal.pone.0174613.t007

###### Sensitivity analysis.

![](pone.0174613.t007){#pone.0174613.t007g}

  Risk Factor                                         ≥3 (n = 78)   \<3 (n = 444)   n =   Total   \%     Univariate   Regression---Forward Step Wald   Regression---Enter Method   Regression---Backward Wald                                                                  
  --------------------------------------------------- ------------- --------------- ----- ------- ------ ------------ -------------------------------- --------------------------- ---------------------------- ----------- ------- ----- ----------- ------- ----- ---------- -------
  Currently not in a relationship                                                                                                                                                                                                                                              
   No                                                 17            207             224           7.6                                                                                                                                                                          
   Yes                                                61            237             298   522     20.5   3.1          1.8--5.5                         \<0.001                     2.6                          1.4--5.0    0.002   3.3   1.5--7.3    0.004   3.0   1.4--6.5   0.006
  Born in Australia                                                                                                                                                                                                                                                            
   No                                                 15            186             201           7.5                                                                                                                                                                          
   Yes                                                63            258             321   522     19.6   3.0          1.7--5.5                         \<0.001                     2.7                          1.4--5.1    0.003   2.4   1.2--4.9    0.014   2.3   1.1--4.7   0.019
  Medicare Safety Net reached in previous 12 months                                                                                                                                                                                                                            
   No                                                 49            343             392           12.5                                                                                                                                                                         
   Yes                                                29            101             130   522     22.3   2.1          1.2--3.7                         0.009                       2.1                          1.2--3.9    0.013   2.2   1.1--4.5    0.024   2.2   1.1--4.4   0.022
  Major Depressive Disorder (PHQ-9)                                                                                                                                                                                                                                            
   No                                                 49            386             435           11.3                                                                                                                                                                         
   Yes                                                29            58              87    522     33.3   3.9          2.3--6.7                         \<0.001                     2.1                          1.1--3.9    0.025                                              
  Marijuana use ≥monthly                                                                                                                                                                                                                                                       
   No                                                 52            376             428           12.1                                                                                                                                                                         
   Yes                                                26            68              94    522     27.7   2.8          1.6--4.7                         \<0.001                     1.9                          1.0--3.5    0.044                                              
  Receives home care services                                                                                                                                                                                                                                                  
   No                                                 70            438             508           13.8                                                                                                                                                                         
   Yes                                                8             6               14    522     57.1   8.3          2.8--24.8                        \<0.001                     5.0                          1.5--16.5   0.009   4.4   1.0--18.8   0.046                    
  Participates in HIV Community Organisations                                                                                                                                                                                                                                  
   No                                                 56            389             445           12.6                                                                                                                                                                         
   Yes                                                22            55              77    522     28.6   2.8          1.6--4.9                         \<0.001                     2.3                          1.2--4.4    0.012   2.4   1.1--5.4    0.033   2.3   1.1--5.0   0.032
  Necessity Concerns score \> sample mean                                                                                                                                                                                                                                      
   No                                                 30            247             277           10.8                                                                                                                                                                         
   Yes                                                48            197             245   522     19.6   2.0          1.2--3.3                         0.005                       1.8                          1.0--3.1    0.050                                              
  Starting ART following patient request                                                                                                                                                                                                                                       
   No                                                 61            397             458           13.3                                                                                                                                                                         
   Yes                                                17            47              64    522     26.6   2.3          1.3--4.3                         0.006                       2.7                          1.3--5.5    0.005   3.0   1.3--7.0    0.012   3.0   1.3--6.9   0.008
  Living in subsidized housing                                                                                                                                                                                                                                                 
   No                                                 56            362             418           13.4                                                                                                                                                                         
   Yes                                                22            82              104   522     21.2   1.7          1.0--3.0                         0.047                                                                        2.5   1.0--6.2    0.045   2.7   1.1--6.3   0.023
  Having difficulty with ART pharmacy access                                                                                                                                                                                                                                   
   No                                                 67            423             490           13.7                                                                                                                                                                         
   Yes                                                11            21              32    522     34.4   3.3          1.5--7.2                         0.001                                                                                                  2.8   1.0--7.6   0.050

Notable variables that were significant in bivariate, but not multivariate, analysis included ART-specific factors (non-single-tablet regimens, greater than once-daily ART dosing), injection drug use, and other markers of socioeconomic status (notably low income, unemployment, financial strain and cost barriers to ART access).

Discussion {#sec021}
==========

In our cohort of adults with HIV in Australia, with a median of three years of sustained viral suppression, 15% self-reported suboptimal ART adherence over the previous three months at a level that is likely to place them at increased risk of ART failure.

Other studies of self-reported ART adherence found similar or higher findings of suboptimal adherence. The average rate of reporting ≥90% adherence is estimated to be 62% \[[@pone.0174613.ref009]\]. One anonymous, community-based online survey (HIV Futures 7) found that about 20% of 1,058 HIV-positive, Australian adults reported \<90% adherence \[[@pone.0174613.ref048]\]. While viral suppression in Australia is estimated to be 92% of those engaged in care; this represents only 68% of those diagnosed \[[@pone.0174613.ref010]\], it is unknown how much of that gap is represented by non-adherence.

We found several factors to be independently associated with suboptimal ART adherence, including socioeconomic, cultural, social, relationship, and patient engagement factors, but not clinical or ART regimen-related factors. Of these, 3 variables were common to all analyses: reaching the Medicare safety net, receiving home care services, and self-requesting ART.

Being born in Australia was associated with less adherence in our sample, which is supported by a higher rate of loss to follow-up in Australian-born individuals within another Australian cohort \[[@pone.0174613.ref049]\]; adherence data is not collected in that cohort. Mills et al \[[@pone.0174613.ref050]\] showed significantly higher adherence to ART in sub-Saharan Africa (77%) compared to North America (55%). Ortego et al \[[@pone.0174613.ref009]\] in meta-analysis found that participants in countries with high Human Development Index (HDI) had lower adherence rates than those with low HDI. However, in our sample, of those not born in Australia, the country of birth was most likely to be in the United Kingdom or New Zealand, where national healthcare is similarly available. In our cohort, there was a higher proportion of low-income earners in those who were Australian born, and a higher proportion of women in those born overseas; while other characteristics between the groups were similar.

Not being in a relationship was also independently associated with lower ART adherence. Other research has found adherence levels to increase with perceived quality of the relationship, and also with a partner's support of ART \[[@pone.0174613.ref051]\].

About 20% of our cohort initiated ART with the aim of preventing transmission to others, and 12% at his/her own request. Therefore, it is noteworthy that suboptimal ART adherence was more common if the primary reason for having started ART was the patient's own request. This is important, as the purpose of initiating ART, for personal or public health benefit, may influence a patient's likelihood for adherence. Recently, in a study of HIV serodiscordant couples investigating ART as prevention of HIV (HPTN 052), high levels of ART adherence by pill count and self-report were reported in those initiating ART as prevention \[[@pone.0174613.ref052]\]. Good mental health was the only factor significantly associated with optimal ART adherence. HPTN 052 provides the only prospective adherence data regarding predictors of ART adherence in a population who initiated ART treatment as a means for prevention of HIV transmission. The participants were under clinical trial conditions, and actively received adherence counselling throughout the study visits, whether the same high levels of adherence will be achieved in the real world is unknown. Moreover, the investigators defined high-level adherence as ≥80% of prescribed doses, which is a lower threshold than we examined. Assessment of adherence over time in those who started ART at their own request will be important to follow-up in our cohort. We are unable to explain why those participants who self-requested ART (seemingly motivated therefore to initiate ART) would be less adherent. It may be that patients self-requesting ART may be doing so for reasons such as onward transmission (e.g. pressure from sexual partners or media), or lack of education around ART requirements or side effects once started. Also, given that our sample is highly treatment-experienced, it is possible that some of the patients self-requesting ART did so after an ART break \[[@pone.0174613.ref004]\].

One financial indicator independently associated with suboptimal ART adherence in our sample was living in subsidized housing. In comparison, one systematic review of five studies found that medication adherence was positively associated with housing stability in HIV-infected adults \[[@pone.0174613.ref053]\]. However, living in subsidized housing, as assessed in our study, does not necessarily imply that the housing is unstable (e.g. transient). The implication that subsidised housing may not represent housing stability is important; as one study found that residents in long-term public housing had better ART adherence than those in short-term or transient housing situations (e.g. hostels or shelters) \[[@pone.0174613.ref054]\].

In our sample, reaching the Medicare safety net was positively associated with suboptimal adherence. Housing status and meeting Medicare safety net thresholds may reflect broader differences in socioeconomic status (SES). Lower SES has been associated with poorer treatment outcomes in HIV, although this has predominantly been investigated in the United States where subsidised healthcare was not universally available \[[@pone.0174613.ref016]\], while our sample overwhelmingly has access to subsidized healthcare, as in western Europe and Canada for example. Those patients who meet the Medicare safety net threshold are more likely to have multiple comorbidities, given that the threshold is met by service utilisation. It may be that exceeding the Medicare safety net thresholds places participants at such a high level of financial strain that ART delay or interruption follows. This would suggest that lowering the Medicare safety net threshold may improve ART adherence. While the ART co-payment costs to participants were not associated with suboptimal adherence, this is just one component of the financial burden that contributes to meeting the Medicare safety net threshold (thereby reduced once the threshold is met). Recently (01 October 2015), the ART co-payment was removed in the state of New South Wales. Other jurisdictions in Australia still apply a co-payment, while some do not (or never have). The influence this has on ART adherence in different jurisdictions and over time is yet to be determined.

Suboptimal adherence also associated with home-care services and linkage to HIV-community organisations / outreach. These covariates may also be indicative of other factors that exacerbate non-adherence, as they may be the result of a higher dependency on medical care, or self-identified requirements to engage in outreach, for example, patients with chronic or more complex needs. These variables are unlikely to be the cause of low adherence per se, but rather may be a result of complex sets of factors that predispose to low adherence, such as low income, higher healthcare costs, low education, drug use, and mental ill-health.

Sensitivity analysis was conducted, fitting the model after reclassifying 23 participants from the "sub-optimally adherent" group as they were on twice-daily ART dosing. The two analyses overlapped in that statistically significant variables in the reduced sample were reaching the Medicare safety net, receiving home care services, and self-requesting ART; and of borderline statistical significance was injecting crystal methamphetamine. Importantly, 11 of these 23 participants were on a once-daily backbone therapy. It is unknown from our data which / what ART dose was missed.

Our study looked at a comprehensive set of factors that may influence adherence. In multivariate analysis, ART medications and regimens (e.g. STRs) were not as important as socioeconomic, cultural, social indicators or participant preference to start ART. Other factors, such as injection drug use and depression, were also no longer significant following regression analysis. Also contrary to previous work in the US which concentrated on more advanced HIV-positive cases with a higher prevalence of HIV-associated dementia \[[@pone.0174613.ref026]\], we did not find an association with neurocognitive impairment.

Our data suggest that improvements in ART dosing and tolerability may have less effect on improving adherence than will addressing the modifiable variables we found to be associated with suboptimal adherence. The findings of the current study arguably suggest that interventions designed specifically for this vulnerable part of the Australian population are further needed as, despite current supports, it is possible that complex and combined life stresses associated with lower socio-economic status in high-income countries lead to non-optimal adherence and so the risk of disease progression.

Our study has limitations. Adherence was based solely on participant self-report; which may overestimate true adherence \[[@pone.0174613.ref055]\]. Hence it is possible that suboptimal adherence is underestimated in this sample. It should be noted, however, that all participants had achieved sustained viral suppression. Our study did not collect refusal rates during recruitment due to the nature of establishing a multi-site clinical cohort, relying on divergent local site management. This limitation is of particular importance to the risk of selection bias, if there are a subset of patients who were considered ineligible by the sites or themselves unwilling to complete the questionnaire (e.g. given the length of time involved).

Findings may not generalise to other population groups, such as women and heterosexual men, to patients who are experiencing virological failure, or to other settings, such as one without access to free or highly subsidized ART, community supports or social housing. The sample and setting of this study nevertheless captures the community most affected by HIV in Australia \[[@pone.0174613.ref056]\] and it is reassuring that our cohort's demographics are very similar to the national demographic data \[[@pone.0174613.ref057]\].

There is a risk that in such a comprehensive data-set, there will be co-linearity between some variables. We chose to use a multivariable regression model, as the aim was to identify variables that could be easily identified in a clinical consult, to enable healthcare workers to determine allocation of adherence-improving resources in a clinically meaningful way; and for this reason using multivariable regression modelling and conducting sensitivity analyses was the approach chosen. Other studies investigating correlates of adherence have used similar approaches \[[@pone.0174613.ref058]\].

In the current era of early and lifelong ART, it is imperative that a patient's likelihood for suboptimal adherence be assessed at regular intervals, and that those who would benefit from adherence interventions are identified and offered appropriate supports. From a broadly scoped, multi-dimensional assessment we identified a limited number of variables independently associated with suboptimal adherence. These variables are not routinely monitored in clinical care, cohort studies or clinical trials; but could be incorporated into these settings. These variables provide information that could be readily assessed prior to ART initiation and periodically whilst receiving ART as indicators of an elevated risk of suboptimal adherence. It will be important to undertake a longitudinal assessment of associations between covariates and suboptimal adherence, drawing on the data prospectively collected in the current study, to gauge if the predictors of incident and sustained low adherence are similar to covariates identified in the current report.
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